



American College of Clinical Pharmacy Research Institute

13000 West 87th Street Parkway

Lenexa, KS 66215

(913) 492-3311

www.accpri.org

PRESS RELEASE

FOR IMMEDIATE RELEASE

December 15, 2016

CONTACT: Rachel Chennault

Director, ACCP PBRN

rchennault@accp.com

ACCP Research Institute Announces Collaborative Research Partnership with Tabula Rasa HealthCare

Lenexa, Kansas – The American College of Clinical Pharmacy Research Institute today announced a new partnership to support research combining the use of an individual’s genetic makeup with that of a unique clinical decision support system to help guide medication choices in primary care settings. The new partner, Tabula Rasa HealthCare (TRHC), provides health care organizations with patient-specific, data-driven technology to optimize medication choices to improve patient outcomes, reduce hospitalizations, lower health care costs, and manage risk.

“The movement towards using personal genetic information to inform drug choices is becoming a reality, and many people know that genetic information can be used to guide the choice or dose of a newly prescribed medication,” said Kevin Bain, Pharm.D., MPH, Vice President of Medication Risk Mitigation at TRHC. “It is by combining clinical decision support systems and genetic information that the most accurate prediction of drug response is achieved,” said Veronique Michaud, BPharm, Ph.D., Vice President, Scientific Affairs at TRHC. “TRHC’s medication risk mitigation software offers this type of information at the point of care.”

The new collaborative research program will begin with a pilot study, titled “Pharmacogenomics and Clinical Decision Support Systems for Advancing Patient Care in Depression ($\frac{PGx}{CDSS} = APCD$) Study.” Its purpose is to evaluate the integration of pharmacogenomic testing using a clinical decision support system from a medication risk mitigation tool into the treatment of major depressive disorder in primary care practice settings. Early in 2017, the American College of Clinical Pharmacy Research Institute Practice-Based Research Network (ACCP PBRN) will enroll clinical pharmacists and their respective primary care practices in this 15-month study.

“Predicting an individual patient’s response to a particular antidepressant is clinically challenging. This implementation pilot will investigate how clinical pharmacists who possess the necessary training and skills to interpret pharmacogenomic results incorporate clinical decision support from a medication risk mitigation tool to make therapeutic recommendations as they assist and collaborate with primary care providers in the drug decision-making process,” said Debra J. Barnette, Pharm.D., FCCP, BCPS, BCACP, CDE, Assistant Professor from Ohio State University and Principal Investigator for the project. “This is an exciting time for pharmacy. Across the country, pharmacists are taking the lead in the area of

pharmacogenetic testing. The use of this tool in primary care has the potential to significantly impact patient care.”

The DARTNet Institute, a partner in the effort, will capture data for this study from patient medical records and collect patient-reported outcomes through questionnaires. “DARTNet will provide the ability to use embedded data transfer systems from electronic health records to present detailed patient information to Tabula Rasa HealthCare and back to the treating clinicians – both clinical pharmacists and medical clinicians. DARTNet is excited about working with the ACCP PBRN and Tabula Rasa HealthCare to create a system that will allow other practices to consider this approach to medication prescribing,” said Dr. Wilson Pace, Chief Medical Officer for the DARTNet Institute.

Funding for this pilot study is being provided by Tabula Rasa HealthCare and will include partial use of TRHC’s proprietary medication risk mitigation software, MedWise Advisor®, at participating study sites. The MedWise Advisor Medication Risk Mitigation Platform provides access to clinical pharmacists participating in the study to a clinical decision support tool when conducting comprehensive evaluations of patients’ medications, conditions, and pharmacogenomic testing results to make prescribing recommendations to their physician colleagues. “Personalized healthcare has been knocking at our door for some time. Development of technological solutions based on scientific knowledge by TRHC will allow the clinical application of a personalized and comprehensive approach towards medication management,” said Jacques Turgeon, BPharm, Ph.D., Chief Scientific Officer at TRHC.

About ACCP RI

The American College of Clinical Pharmacy Research Institute is a nonprofit organization whose mission is to advance pharmacotherapy through support and promotion of research, training, and education. It is committed to uncompromising excellence in scholarship, education, and research while expanding the impact of clinical pharmacy professionals across the entire health care community. For more information about the ACCP RI, visit www.accpri.org.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable health care organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower health care costs, and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers, and other health care organizations. For more information, please visit www.TRHC.com.

About DARTNet Institute

The DARTNet Institute represents a collaboration of practice-based research networks conducting research using data from electronic health records, claims, and patient-reported outcomes across the United States.